Citadel Advisors
TYRA icon

Citadel Advisors’s Tyra Biosciences TYRA Stock Holding History

Citadel Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.89M Buy
278,307
+262,911
+1,708% +$8.7M ﹤0.01% 3745
2026
Q1 		$590K Buy
+15,396
New +$498K ﹤0.01% 8899
2025
Q4 		– Sell
-111,293
Closed -$2.04M – 14113
2025
Q3 		$1.56M Sell
111,293
-104,843
-49% -$1.2M ﹤0.01% 6582
2025
Q2 		$2.07M Buy
216,136
+119,854
+124% +$1.14M ﹤0.01% 5647
2025
Q1 		$895K Buy
96,282
+40,695
+73% +$527K ﹤0.01% 7209
2024
Q4 		$773K Buy
55,587
+31,635
+132% +$574K ﹤0.01% 7584
2024
Q3 		$563K Buy
+23,952
New +$503K ﹤0.01% 8010
2024
Q2 		– Sell
-16,789
Closed -$275K – 15442
2024
Q1 		$275K Buy
+16,789
New +$275K ﹤0.01% 9647
2023
Q1 		– Sell
-26,717
Closed -$203K – 15536
2022
Q4 		$203K Sell
26,717
-13,902
-34% -$98.3K ﹤0.01% 10108
2022
Q3 		$357K Sell
40,619
-34,226
-46% -$313K ﹤0.01% 9200
2022
Q2 		$535K Sell
74,845
-3,464
-4% -$27.6K ﹤0.01% 8493
2022
Q1 		$838K Sell
78,309
-4
-0% -$47 ﹤0.01% 8117
2021
Q4 		$1.1M Buy
+78,313
New +$1.56M ﹤0.01% 7711

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Citadel Advisors's TYRA Position: Q2 2026 in Review

Citadel Advisors increased its Tyra Biosciences (TYRA) stake by 1,708% in Q2 2026, buying an estimated $8.7M and bringing the position to 278,307 shares worth $8.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3745.

Citadel Advisors first reported a position in TYRA in Q4 2021 and has held it in 13 quarters since. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Citadel Advisors held 278,307 shares of Tyra Biosciences worth $8.89M as of Q2 2026.
  • Citadel Advisors bought 262,911 Tyra Biosciences shares in Q2 2026, an estimated $8.7M.
  • Tyra Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3745 holding.
  • Citadel Advisors first reported a position in Tyra Biosciences in Q4 2021 and has held it in 13 quarters since.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.